BioLargo Statistics
Total Valuation
BioLargo has a market cap or net worth of 58.05 million. The enterprise value is 53.00 million.
| Market Cap | 58.05M |
| Enterprise Value | 53.00M |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLargo has 301.06 million shares outstanding. The number of shares has increased by 4.60% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 301.06M |
| Shares Change (YoY) | +4.60% |
| Shares Change (QoQ) | +1.37% |
| Owned by Insiders (%) | 6.13% |
| Owned by Institutions (%) | 0.51% |
| Float | 258.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.08 |
| PB Ratio | 6.77 |
| P/TBV Ratio | 6.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -25.04 |
| EV / Sales | 2.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -19.65 |
Financial Position
The company has a current ratio of 2.31, with a Debt / Equity ratio of 0.24.
| Current Ratio | 2.31 |
| Quick Ratio | 2.22 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.53 |
| Interest Coverage | -107.29 |
Financial Efficiency
Return on equity (ROE) is -74.20% and return on invested capital (ROIC) is -32.96%.
| Return on Equity (ROE) | -74.20% |
| Return on Assets (ROA) | -24.67% |
| Return on Capital (ROIC) | -32.96% |
| Revenue Per Employee | 577,875 |
| Profits Per Employee | -66,156 |
| Employee Count | 33 |
| Asset Turnover | 2.19 |
| Inventory Turnover | 57.23 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.07% in the last 52 weeks. The beta is 0.19, so BioLargo's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +9.07% |
| 50-Day Moving Average | 0.20 |
| 200-Day Moving Average | 0.26 |
| Relative Strength Index (RSI) | 50.25 |
| Average Volume (20 Days) | 358,120 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.06 |
Income Statement
In the last 12 months, BioLargo had revenue of 18.49 million and -2.12 million in losses. Loss per share was -0.01.
| Revenue | 18.49M |
| Gross Profit | 8.19M |
| Operating Income | -3.33M |
| Pretax Income | -3.64M |
| Net Income | -2.12M |
| EBITDA | -3.20M |
| EBIT | -3.33M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 3.88 million in cash and 1.43 million in debt, giving a net cash position of 2.45 million or 0.01 per share.
| Cash & Cash Equivalents | 3.88M |
| Total Debt | 1.43M |
| Net Cash | 2.45M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 5.98M |
| Book Value Per Share | 0.03 |
| Working Capital | 4.19M |
Cash Flow
In the last 12 months, operating cash flow was -1.29 million and capital expenditures -1.41 million, giving a free cash flow of -2.70 million.
| Operating Cash Flow | -1.29M |
| Capital Expenditures | -1.41M |
| Free Cash Flow | -2.70M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 44.29%, with operating and profit margins of -17.99% and -11.45%.
| Gross Margin | 44.29% |
| Operating Margin | -17.99% |
| Pretax Margin | -19.66% |
| Profit Margin | -11.45% |
| EBITDA Margin | -17.32% |
| EBIT Margin | -17.99% |
| FCF Margin | n/a |
Dividends & Yields
BioLargo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.60% |
| Shareholder Yield | -4.60% |
| Earnings Yield | -3.72% |
| FCF Yield | -4.65% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioLargo has an Altman Z-Score of -8.69. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.69 |
| Piotroski F-Score | n/a |